{"entity":{"id":"neratinib-diarrhoea-prophylaxis-and-dose-escalation","kind":"protocol","name":"Neratinib: diarrhoea prevention with loperamide or dose escalation","aka":["neratinib diarrhoea prophylaxis","Nerlynx loperamide schedule","neratinib dose escalation","CONTROL trial strategies"],"tldr":"Neratinib, a tablet for HER2-positive breast cancer, causes diarrhoea in almost everyone. Prevent it in one of two ways agreed before you start: loperamide on a fixed schedule from the first tablet for eight weeks, or a lower starting dose built up over two weeks. Drink about two litres a day, and call your team at once if diarrhoea is severe or comes with weakness, dizziness or fever.","summary":"Without prophylaxis, diarrhoea occurred in 95 per cent of people in ExteNET, grade 3 in 40 per cent, with a median onset of grade 3 or worse at day 8. The US label now offers two strategies from the first dose. Either loperamide prophylaxis for the first 56 days (4 mg three times daily in weeks 1 and 2, 4 mg twice daily in weeks 3 to 8, then as needed up to 16 mg a day, titrated to one or two bowel movements a day), or a two-week neratinib dose escalation (120 mg a day in week 1, 160 mg in week 2, 240 mg from week 3) with loperamide as needed. In the open-label phase II CONTROL trial, six non-comparative cohorts of 563 people starting extended adjuvant neratinib all had less grade 3 diarrhoea than historical controls; it was lowest with the two-week escalation (13 per cent) and highest with colestipol plus loperamide as needed (33 per cent), and diarrhoea-related discontinuations were 3 per cent with the two-week escalation against 20 per cent with loperamide alone. The label's dose modification table sets when to adjust antidiarrhoeals, interrupt, reduce or stop.","asOf":"2026-11-11","links":[],"tags":["protocol","diarrhoea","supportive-care"],"related":["treatment-induced-diarrhoea-grading-and-management","capecitabine"],"cancers":["breast-her2-positive"],"sections":["supportive-care"],"technologies":["her2-tyrosine-kinase-inhibitors"],"targets":[],"drugs":["neratinib"],"companies":["puma-biotechnology"],"institutions":[],"pathways":[],"terms":["ctcae-grading"],"trials":["nala"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"simple":"This cancer tablet often gives runny poo. Your team will either give you a medicine to take every day at the start or start with a smaller dose. Call them if it is bad.","domain":"oral-anticancer-therapy","setting":{"who":["doctor","pharmacist","nurse","patient-or-carer"],"where":["outpatient-clinic","home","telephone-triage"]},"population":"Adults starting neratinib for HER2-positive breast cancer: extended adjuvant treatment of early-stage disease, or with capecitabine for metastatic disease. CONTROL enrolled only people starting extended adjuvant neratinib after trastuzumab-based therapy. The label's dose modification table read here is for neratinib monotherapy; with capecitabine, capecitabine has its own rules.","trigger":"Neratinib is prescribed.","steps":[{"action":"Before the first tablet, agree one strategy: loperamide prophylaxis for the first 56 days, or a two-week neratinib dose escalation","why":"Diarrhoea usually starts in the first weeks; either strategy, started on day one, makes severe diarrhoea much less likely.","source":"nerlynx-label-2026","quote":"Alternatively, a 2-week NERLYNX dose escalation approach prior to initiation of the recommended treatment regimen with NERLYNX can also be considered for diarrhea management"},{"action":"If using prophylaxis, start loperamide with the first dose: 4 mg three times daily for days 1 to 14, 4 mg twice daily for days 15 to 56, then 4 mg as needed up to 16 mg a day","why":"Taking loperamide on a schedule from the start keeps diarrhoea mild while the bowel adapts.","source":"nerlynx-label-2026","quote":"Weeks 1–2 (days 1–14) 4 mg three times daily Weeks 3–8 (days 15–56) 4 mg twice daily Weeks 9–Discontinuation of NERLYNX 4 mg as needed, not to exceed 16 mg per day; titrate dosing to achieve 1–2 bowel movements per day"},{"action":"If using dose escalation, give 120 mg daily in week 1, 160 mg daily in week 2 and 240 mg daily from week 3, with antidiarrhoeals as needed","why":"A lower dose at first lets the bowel adjust before the full dose; in the CONTROL trial it gave the least severe diarrhoea.","source":"nerlynx-label-2026","quote":"Week 1 (days 1–7) 120 mg daily (three 40 mg tablets) Week 2 (days 8–14) 160 mg daily (four 40 mg tablets) Week 3 and onwards 240 mg daily (six 40 mg tablets, recommended dose)"},{"action":"Titrate loperamide to one or two bowel movements a day, and ask the person to keep to that target","why":"One or two bowel movements a day shows the dose is right: fewer suggests too much loperamide, more that diarrhoea is building.","source":"nerlynx-label-2026","quote":"Instruct patients to maintain 1–2 bowel movements per day and on how to use antidiarrheal treatment regimens."},{"action":"For grade 1, grade 2 lasting up to 5 days, or grade 3 lasting up to 2 days, adjust antidiarrhoeals, change diet and keep fluid intake around 2 litres a day","why":"Most diarrhoea on neratinib settles with more antidiarrhoeal medicine and fluids without stopping the drug.","source":"nerlynx-label-2026","quote":"Adjust antidiarrheal treatment Diet modifications Fluid intake of ~2 L/day should be maintained to avoid dehydration"},{"action":"Interrupt neratinib for diarrhoea with complicating features (dehydration, fever, low blood pressure, kidney failure, grade 3 or 4 neutropenia), grade 2 lasting more than 5 days or grade 3 more than 2 days despite treatment; resume at the same dose if it settles within a week, otherwise at a reduced dose","why":"Stopping briefly lets the bowel recover; restarting at a lower dose after a slow recovery prevents a repeat.","source":"nerlynx-label-2026","quote":"If diarrhea resolves to ≤Grade 1 in one week or less, then resume NERLYNX treatment at the same dose If diarrhea resolves to ≤Grade 1 in longer than one week, then resume NERLYNX treatment at reduced dose"},{"action":"Stop neratinib permanently for grade 4 diarrhoea, or if grade 2 or worse diarrhoea recurs at 120 mg a day","why":"Life-threatening diarrhoea, or diarrhoea that persists at the lowest dose, means the drug cannot be given safely.","source":"nerlynx-label-2026","quote":"Permanently discontinue NERLYNX treatment Diarrhea recurs to Grade 2 or higher at 120 mg per day Permanently discontinue NERLYNX treatment"},{"action":"Ask the person to call immediately for severe diarrhoea, or diarrhoea with weakness, dizziness or fever","why":"Severe diarrhoea on neratinib has led to dehydration, low blood pressure and kidney failure.","source":"nerlynx-label-2026","quote":"Advise patients to inform their healthcare provider immediately if severe (≥Grade 3) diarrhea or diarrhea associated with weakness, dizziness, or fever occurs during treatment with NERLYNX"}],"bestInClass":{"statement":"The current US label (July 2026) makes both strategies standard from the first dose: scheduled loperamide for 56 days, or a two-week dose escalation with loperamide as needed. On the evidence read, the two-week escalation gave the lowest rates of grade 3 diarrhoea (13 per cent) and of diarrhoea-related discontinuation (3 per cent) in CONTROL, against 31 and 20 per cent with loperamide alone; but CONTROL's cohorts were not randomised against each other, so the comparison is indirect. No graded guideline on neratinib diarrhoea was found.","sources":["nerlynx-label-2026","control-2023"]},"variants":[{"name":"Four-week dose escalation (CONTROL DE2)","differs":"Neratinib 160 mg a day on days 1 to 14 and 200 mg a day on days 15 to 28, then 240 mg, with loperamide as needed.","evidence":"Grade 3 diarrhoea 27 per cent and diarrhoea-related discontinuation 6 per cent, both higher than the two-week schedule; not in the label. Open-label, non-comparative cohort.","sources":["control-2023"]},{"name":"Loperamide plus budesonide (CONTROL BL)","differs":"Adds budesonide 9 mg once daily on days 1 to 28 to scheduled loperamide.","evidence":"Grade 3 diarrhoea 28 per cent and diarrhoea-related discontinuation 11 per cent, against 31 and 20 per cent with loperamide alone. Open-label, non-comparative cohort.","sources":["control-2023"]},{"name":"Loperamide plus colestipol (CONTROL CL and CL-PRN)","differs":"Adds the bile acid binder colestipol 2 g twice daily on days 1 to 28, to scheduled loperamide (CL) or to loperamide as needed (CL-PRN).","evidence":"Grade 3 diarrhoea 21 per cent with scheduled loperamide and 33 per cent with loperamide as needed; discontinuations 4 and 8 per cent. Open-label, non-comparative cohorts. The label says other agents may be added to loperamide as clinically indicated.","sources":["control-2023","nerlynx-label-2026"]}],"grades":[{"claim":"Grade 3 diarrhoea and discontinuation by strategy in CONTROL","grade":"open-label phase II, six non-comparative cohorts (n = 563)","source":"control-2023","quote":"All strategies reduced grade ≥3 diarrhea with the lowest incidence in DE1 (DE1 13%; colestipol + loperamide [CL] 21%, DE2 27%; budesonide + loperamide [BL] 28%; loperamide [L] 31%; colestipol + loperamide as needed [CL-PRN] 33%)."},{"claim":"Without required prophylaxis (ExteNET), grade 3 diarrhoea occurred in 40 per cent","grade":"Label incidence from the registration trial","source":"nerlynx-label-2026","quote":"In the NERLYNX arm, Grade 3 diarrhea occurred in 40% and Grade 4 diarrhea occurred in 0.1% of patients."}],"sources":[{"key":"nerlynx-label-2026","label":"NERLYNX (neratinib) tablets: US prescribing information","publisher":"Puma Biotechnology, via DailyMed, US National Library of Medicine","year":2026,"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d1e41dcf-e82a-47c2-a0ad-6c6eef621834","gradingScheme":"Product labelling; not graded.","read":"full-text","accessed":"2026-11-11"},{"key":"control-2023","label":"Final findings from the CONTROL trial: strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer","publisher":"The Breast","year":2023,"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9982309/","doi":"10.1016/j.breast.2022.12.003","read":"full-text","accessed":"2026-11-11"}],"upgrades":["idea-upgrade-neratinib-two-week-dose-escalation-by-default"],"gaps":["No randomised comparison of the strategies exists in the sources read: CONTROL's cohorts were enrolled one after another and compared with historical controls.","The EU summary of product characteristics was not read; whether it includes the dose escalation option is not shown here.","No graded guideline on neratinib diarrhoea was found; the general ESMO diarrhoea guideline (2018) could not be read.","CONTROL studied extended adjuvant neratinib only; in metastatic disease with capecitabine (NALA), anti-diarrhoeal prophylaxis was required in the first cycle and the strategies were not compared."]},"route":"/protocols/neratinib-diarrhoea-prophylaxis-and-dose-escalation/","neighbours":{"protocol":[{"id":"treatment-induced-diarrhoea-grading-and-management","kind":"protocol","name":"Diarrhoea from chemotherapy, targeted therapy and radiotherapy: grading, loperamide, octreotide and when to admit","route":"/protocols/treatment-induced-diarrhoea-grading-and-management/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"neratinib","kind":"drug","name":"Neratinib","route":"/drugs/neratinib/"}],"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"}],"section":[{"id":"supportive-care","kind":"section","name":"Supportive Care & Survivorship","route":"/fronts/supportive-care/"}],"technology":[{"id":"her2-tyrosine-kinase-inhibitors","kind":"technology","name":"HER2 tyrosine kinase inhibitors","route":"/technologies/her2-tyrosine-kinase-inhibitors/"}],"company":[{"id":"puma-biotechnology","kind":"company","name":"Puma Biotechnology","route":"/companies/puma-biotechnology/"}],"term":[{"id":"ctcae-grading","kind":"term","name":"CTCAE toxicity grading (grade 3-4 adverse events)","route":"/terms/ctcae-grading/"}],"trial":[{"id":"nala","kind":"trial","name":"NALA","route":"/trials/nala/"}],"idea":[{"id":"idea-upgrade-neratinib-two-week-dose-escalation-by-default","kind":"idea","name":"Start neratinib at a lower dose and build up over two weeks, as the default","route":"/ideas/idea-upgrade-neratinib-two-week-dose-escalation-by-default/"}]}}